News & Events

View our Corporate Presentation
Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma Jun 09, 2025 Press Release
Secura Bio Presented New Data from its Phase 2 PRIMO Trial of Copiktra® (Duvelisib) in Relapsed or Refractory Peripheral T-cell Lymphoma and Announced Plans for its Phase 3 TERZO Trial at the 2024 American Society of Hematology Meeting Dec 09, 2024 Press Release
New Combination Data of Secura Bio’s COPIKTRA® (duvelisib) Presented at the 2024 American Society of Hematology Meeting Dec 09, 2024 Press Release
American Society of Hematology 2024: A Multicenter, Open-Label, Phase 3, Randomized Controlled Trial of Duvelisib versus Investigator’s Choice of Gemcitabine or Bendamustine in Patients With Relapsed/Refractory Nodal T-Cell Lymphoma With T Follicular Helper Phenotype (TERZO) Dec 9, 2024 Presentation
American Society of Hematology 2024: Duvelisib in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma: Final Results From the Phase 2 PRIMO Trial Dec 9, 2024 Presentation
Secura Bio Announces Poster Presentation Highlighting New COPIKTRA® (duvelisib) Data for the Treatment of Patients With Peripheral T-Cell Lymphoma and Other Advanced Hematologic Malignancies at the 2024 American Society of Hematology Meeting Nov 06, 2024 Press Release
Secura Bio Appoints Charles R. Romp as Its Chief Executive Officer Oct 15, 2024 Press Release
Secura Bio Appoints Dr. Patrick Vink as Chairman of the Board of Directors Sep 14, 2024 Press Release
Secura Bio Announces the Addition of Two New Board of Directors Members Dec 07, 2023 Press Release
Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib for the Treatment of Patients with Peripheral T-cell Lymphoma Jan 09, 2023 Press Release
Back to top